Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus حسب Dimitrios, Patoulias

"…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل

Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants حسب Bin, Zhou

احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل

Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants حسب Bin, Zhou

احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل

Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 حسب Fiona B, Bennitt

احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل